Anaveon is a technology company.
Anaveon is a global clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs, focusing on immunology and protein engineering.
Anaveon has raised $155.0M across 2 funding rounds.
Anaveon has raised $155.0M in total across 2 funding rounds.
Anaveon has raised $155.0M in total across 2 funding rounds.
Anaveon's investors include Forbion, High-Tech Gründerfonds, Kurma Partners, Therese Liechtenstein, Novartis Venture Fund, Omega Funds, Pfizer Venture Investments, Pontifax Venture Capital, Seroba Life Sciences, Vincent Brichard.
Anaveon is a clinical-stage biopharmaceutical company developing novel immunotherapies that harness the immune system to treat cancers and immune-mediated diseases with high unmet needs.[1][2][4] Its lead products include ANV-419 (IL-2R agonist for metastatic melanoma, Phase 2) and ANV-600 (IL-2Rβγ x PD-1 bispecific for advanced solid tumors, Phase 2), targeting effector T-cell enhancement to boost anti-tumor responses.[2][5][6] Founded in 2017 and headquartered in Basel, Switzerland, Anaveon has raised over 146 million CHF from high-profile investors, employing a team of immunology, protein engineering, and clinical experts to advance its pipeline from discovery through Phase 2 trials.[1][3][6]
The company serves oncology patients and those with inflammatory/autoimmune conditions, solving the problem of immune system dysfunction by selectively activating T-cells while minimizing toxicity, as seen in ongoing trials and preclinical data presentations.[1][2][5]
Anaveon was founded on December 11, 2017, by Onur Boyman and Andreas Katopodis, scientists and industry experts with deep roots in immunology and immuno-oncology.[1][2] Emerging from breakthroughs in harnessing cytokines like IL-2 and IL-21 to amplify immune responses against tumors, the company started with a focus on protein-engineered therapies to improve safety and efficacy over traditional treatments.[1][5] Early traction came from securing over 146 million CHF in funding, enabling rapid progression to clinical stages, with pivotal moments including Phase 1/2 initiations for ANV-419 (2023) and ANV-600 combinations with PD-1 inhibitors.[2][3][6]
Anaveon rides the bispecific antibody and cytokine engineering wave in immuno-oncology, where market forces favor next-gen IL-2/IL-21 therapies amid PD-1 resistance in solid tumors.[2][5][6] Timing aligns with surging demand for precision immunotherapies—global oncology market projected to grow amid ~20 million annual cancer cases—positioning Anaveon to influence the ecosystem through collaborations and data readouts that validate T-cell selective agonists.[2][6] By addressing immune exhaustion in advanced cancers and autoimmunity, it contributes to the shift from monotherapy to combo regimens, amplifying impact in Switzerland's biotech hub and global trials.[1][4]
Anaveon is poised for Phase 2 readouts in 2025-2026 on ANV-419 and ANV-600, potentially unlocking partnerships or approvals in melanoma/solid tumors, with ANV-700 advancing to IND.[2][6] Trends like AI-driven protein design and multi-specific combos will accelerate its pipeline, while board enhancements signal M&A readiness in a consolidating biotech sector. As it transforms immune insights into therapies, Anaveon's selective T-cell focus could redefine treatments for unmet needs, building on its 2017 vision of immune-powered cures.[1][5]
Anaveon has raised $155.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $120.0M Series B | Forbion, High-Tech Gründerfonds, Kurma Partners, Therese Liechtenstein, Novartis Venture Fund, Omega Funds, Pfizer Venture Investments, Pontifax Venture Capital, Seroba Life Sciences, Vincent Brichard | |
| Feb 1, 2019 | $35.0M Series A | Novartis Venture Fund |